Comparative Economic Value of GLP-1 Obesity Medications Vs Standard Care in Egypt

Obesity is a major public health problem in Egypt, contributing to a high burden of type 2 diabetes (T2DM), cardiovascular disease (CVD), and related healthcare costs. GLP-1 receptor agonists (e.g., semaglutide, marketed as Ozempic/Wegovy) induce substantial weight loss (~15% of body weight) and may reduce obesity-related comorbidities, but their high cost raises questions about affordability and economic value in low-middle-income settings.
To evaluate the long-term economic impact of GLP-1 therapy for obesity versus standard care (no pharmacological intervention) in Egyptian adults with obesity from a healthcare system perspective.
A cohort Markov model was developed for obese Egyptian adults (age 40, BMI ≥30) over a 30-year horizon. Health states included no complications, T2DM, hypertension (HTN), CVD, and death. Transition probabilities were derived from Egyptian/Middle East epidemiological data and clinical trial evidence. Two strategies were compared: (a) chronic GLP-1 therapy for weight loss (with drug costs calibrated to Egyptian pricing) and (b) standard care (lifestyle management only). The model estimated the cumulative incidence of obesity-related diseases and total lifetime medical costs per person (in 2025 USD), including drug and complication treatment costs.
GLP-1 therapy markedly reduced the 30-year cumulative incidence of T2DM (approximately 20% vs 50% under standard care) and CVD events (15% vs 20%), with a moderate reduction in HTN (50% vs 70%). However, lifetime cost per person was much higher with GLP-1 therapy (~$45,000) compared to standard care (~$2,000), an incremental cost of about $43,000 driven primarily by medication expenses.
From the Egyptian healthcare perspective, GLP-1 obesity treatment can substantially improve health outcomes by preventing diabetes and CVD, but at a large financial cost. Unless drug prices fall or treatment is targeted to very high-risk groups, GLP-1 therapy is unlikely to be cost-saving in Egypt. Strategies to improve the cost-effectiveness of pharmacological obesity treatments (such as local price negotiations or selective use in those with prediabetes) are needed to justify widespread adoption in resource-limited health systems.

healthcare, public health, obesity

1. Ezzat, Hossam. “EAPC Country of the Month – Egypt.” European Association of Preventive Cardiology, European Society of Cardiology, October 2014. Accessed April 9, 2026. https://www.escardio.org/communities/associations/eapc/Advocacy/prevention-in-your-country/egypt/.journals. [Google Scholar] [Crossref]

2. Hassanein, Mohamed, Ibrahim Fahmy, Sameh H. Hany, et al. “Epidemiology of and Risk Factors for Type 2 Diabetes in Egypt.” Annals of Global Health 82, no. 5 (2016): 858–870. PDF. Accessed April 9, 2026. https://annalsofglobalhealth.org/articles/1448/files/submission/proof/1448-1-2994-1-10-20180628. [Google Scholar] [Crossref]

3. International Diabetes Federation. “Egypt.” IDF Middle East and North Africa Members. Accessed April 9, 2026. https://idf.org/our-network/regions-and-members/middle-east-and-north-africa/members/egypt/. [Google Scholar] [Crossref]

4. Ibrahim, M. M., Rizk, H., Appel, L. J., El Aroussy, W., Helmy, S., Sharaf, Y., Ashour, Z., Kandil, H., Roccella, E., & Whelton, P. K. (1995). Hypertension prevalence, awareness, treatment, and control in Egypt: Results from the Egyptian National Hypertension Project (NHP). Hypertension, 26(6 I), 886-890. https://doi.org/10.1161/01.HYP.26.6.886 [Google Scholar] [Crossref]

5. Daily News Egypt. “Egypt Wins WHO Global Award for Efforts to Combat Obesity.” September 27, 2025. Accessed April 9, 2026. https://www.dailynewsegypt.com/2025/09/27/egypt-wins-who-global-award-for-efforts-to-combat-obesity/. [Google Scholar] [Crossref]

6. Garvey, W.T., Batterham, R.L., Bhatta, M. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28, 2083–2091 (2022). https://doi.org/10.1038/s41591-022-02026-4 [Google Scholar] [Crossref]

7. Sullivan, Tom. “Diabetes Prevented in 80% of At-Risk Patients Taking Liraglutide.” American Journal of Managed Care, August 18, 2017. Accessed April 9, 2026. https://www.ajmc.com/view/diabetes-prevented-in-80-of-at-risk-patients-taking-liraglutide.pubmed. [Google Scholar] [Crossref]

8. Institute for Clinical and Economic Review (ICER). “Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity.” Press release, August 4, 2022. Accessed April 9, 2026. https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-publishes-evidence-report-on-treatments-for-obesity/. [Google Scholar] [Crossref]

9. Egyptian Streets. “Ozempic’s Surge in Egypt Sparks Medical Praise, Public Demand and Growing Fears.” March 28, 2025. Accessed April 9, 2026. https://egyptianstreets.com/2025/03/28/ozempics-surge-in-egypt-sparks-medical-praise-public-demand-and-growing-fears/. [Google Scholar] [Crossref]

10. Garvey, W.T., Batterham, R.L., Bhatta, M. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28, 2083–2091 (2022). https://doi.org/10.1038/s41591-022-02026-4 [Google Scholar] [Crossref]

11. Piepoli, Massimo F., et al. “Obesity and Cardiovascular Disease: An Executive Document on the European Society of Cardiology Position.” Frontiers in Cardiovascular Medicine 10 (2023): article 1136340. Accessed April 9, 2026. https://www.frontiersin.org/journals/cardiovascular-medcine/articles/10.3389/fcvm.2023.1136340/full. [Google Scholar] [Crossref]

12. Hegazi, R., El-Gamal, M., Abdel-Hady, N., & Hamdy, O. (2015). Epidemiology of and Risk Factors for Type 2 Diabetes in Egypt. Annals of global health, 81(6), 814–820. https://doi.org/10.1016/j.aogh.2015.12.011 [Google Scholar] [Crossref]

• Impact of Foreign Direct Investment in India
• Issues Involved in Digitalisation Special Reference to Indian Tourism Growth
• Relationship Marketing and Customer Loyalty in the Fast-Moving Consumer Goods (FMCG) Industry in Nairobi County
• Financial Literacy or Financial Inclusion? Which is Which, What is What—To Achieve Uganda’s 10-Fold Economic Growth By 2040
• Harnessing Natural Gas for Economic Transformation: Overcoming the Regulatory and Infrastructural Bottlenecks in Nigeria